Xvivo Perfusion ABXVIPF -1.32%91 Days Payable is 41.22 as of Mar. 2026, which is 56% below its 10-year median of 92.95. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 60.88% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Days Payable or its related term are showing as below:
XVIPF'
s Days Payable Range Over the Past 10 Years
Min: 57.71 Med: 92.95 Max: 123.69
Current: 57.71
During the past 13 years, Xvivo Perfusion AB's highest Days Payable was 123.69. The lowest was 57.71. And the median was 92.95.
XVIPF's Days Payable is ranked worse than 60.88% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs XVIPF: 57.71
Xvivo Perfusion AB's Days Payable
declined
from Mar. 2025 (57.04) to Mar. 2026 (41.22).
It may suggest that Xvivo Perfusion ABaccelerated paying its suppliers.
Xvivo Perfusion AB Days Payable Related Terms
Xvivo Perfusion AB Days Payable Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Xvivo Perfusion AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Days Payable of 41.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xvivo Perfusion AB and its competitors. This is 56% below median its historical median of 92.95. Over the past decade, Xvivo Perfusion AB's Days Payable has ranged from 57.71 to 123.69. According to the industry distribution chart, Xvivo Perfusion AB ranks #484 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 60.9%.
Is Xvivo Perfusion AB's Days Payable too high?
Xvivo Perfusion AB's current Days Payable of 41.22 is 56% below median its 10-year median of 92.95. Over the past 10 years, this metric has ranged from a low of 57.71 to a high of 123.69. The Medical Devices & Instruments industry median Days Payable is 67.87. Xvivo Perfusion AB's value of 41.22 is 39.3% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #484 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #484 out of 795 companies for Days Payable. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Days Payable is 67.87. Xvivo Perfusion AB's value of 41.22 is 39.3% below this benchmark. Historically, Xvivo Perfusion AB's own Days Payable has ranged from 57.71 to 123.69 over the past decade. While the company's 10-year median is 92.95 vs. the industry median of 67.87, Xvivo Perfusion AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Days Payable of 41.22 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Days Payable is 41.22, which is 56% below median its own 10-year median of 92.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Days Payable is 41.22, which is 56% below median its 10-year median of 92.95 and 39.3% below the Medical Devices & Instruments industry median of 67.87. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Days Payable is 41.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Days Payable: 41.22 (56% below median its 10-year median of 92.95)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 39.3% below the Medical Devices & Instruments median (#484 of 795)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
